Borders Should No Longer Be Barriers
In Clinical Trials


Final Recommendations are Available!

Cross-Border Access to Clinical Trials

For many patients with life-threatening or rare diseases, participating in a clinical trial abroad is sometimes the only option—but without an EU-wide legal framework or guidance, barriers remain high, and access out of reach.

EU-X-CT is a multi-stakeholder initiative aimed at systematically collecting information on the barriers to cross-border participation in clinical trials within Europe and developing recommendations for enabling better access.

The initiative is a concerted effort by volunteers from patient organisations, academics, research networks, industry, and not-for-profit organisations, led by EFGCP and EFPIA.

Watch the video to learn more: Click Here

EU-X-CT to Launch Final Recommendations at its Public Stakeholder Conference 2025

The EU-X-CT Public Stakeholders’ Conference: Making Cross-Border Access to Clinical Trials a Reality has successfully taken place!

A heartfelt thank you to all delegates for attending The EU-X-CT Public Stakeholders’ Conference! Thanks to everyone who actively contributed in the morning sessions, where we tackled key issues in facilitating cross-border trial access, and to those who shaped the forward-looking discussions in the afternoon sessions, exploring sustainability, impact, and usability.

It has been a day full of meaningful dialogue and collaboration. We appreciate your engagement and look forward to continuing the conversation! Stay tuned for the next steps:

The Conference Report
The Patients Website
And more...

New Tools Available

Our Objectives

Raise Awareness

To connect with existing and new initiatives to raise awareness about current issues that hinder access to clinical trials beyond a patient's home country

Gather Information

To collect comprehensive information on barriers to cross-border clinical trial access covering legal, regulatory, financial, and practical aspects

Publish Recommendations

To develop and publish recommendations to enable better access to cross-border clinical trials

Roadmap

Our Stakeholders

Patient Representation

  • Patients and Carers
  • Patient Advocates
  • Patient organisations

Legal and Regulatory

  • EU and national policymakers
  • Regulators
  • Ethics committees

Insurance

  • Insurance companies
  • Payers

Clinical and Academic

  • Investigators and study groups
  • Pharmaceutical associations
  • Industry and academic sponsors
  • European Research Networks
  • Medical and professional societies

Our Leadership


With the Support of

Gold

Silver

Regular